JP2018511625A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511625A5
JP2018511625A5 JP2017553410A JP2017553410A JP2018511625A5 JP 2018511625 A5 JP2018511625 A5 JP 2018511625A5 JP 2017553410 A JP2017553410 A JP 2017553410A JP 2017553410 A JP2017553410 A JP 2017553410A JP 2018511625 A5 JP2018511625 A5 JP 2018511625A5
Authority
JP
Japan
Prior art keywords
kit
hyperglycemia
chemotherapy
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/028055 external-priority patent/WO2016168802A2/en
Publication of JP2018511625A publication Critical patent/JP2018511625A/ja
Publication of JP2018511625A5 publication Critical patent/JP2018511625A5/ja
Pending legal-status Critical Current

Links

JP2017553410A 2015-04-16 2016-04-18 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬 Pending JP2018511625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168000A Division JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Publications (2)

Publication Number Publication Date
JP2018511625A JP2018511625A (ja) 2018-04-26
JP2018511625A5 true JP2018511625A5 (https=) 2019-01-10

Family

ID=57126369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553410A Pending JP2018511625A (ja) 2015-04-16 2016-04-18 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬
JP2020168000A Pending JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168000A Pending JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Country Status (14)

Country Link
US (2) US20160303056A1 (https=)
EP (2) EP4299061A3 (https=)
JP (2) JP2018511625A (https=)
KR (1) KR20180002677A (https=)
CN (1) CN107613979A (https=)
AU (1) AU2016248443B2 (https=)
BR (1) BR112017022244A2 (https=)
CA (2) CA3108664A1 (https=)
HK (1) HK1249858A1 (https=)
IL (1) IL255026A0 (https=)
MX (1) MX2017013133A (https=)
RU (1) RU2734774C2 (https=)
WO (1) WO2016168802A2 (https=)
ZA (1) ZA201707710B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
JP2019505592A (ja) 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
US11540550B2 (en) 2016-05-11 2023-01-03 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
EP3765046A4 (en) 2018-03-15 2022-04-27 University Of Southern California BUT NOT EXCLUSIVELY WATER-BASED DIET (FMD) FACILITATES THE REVERSAL OF INFLAMMATION AND INFLAMMATORY BOWEL DISEASE
CA3102279A1 (en) 2018-06-01 2019-12-05 Cornell University Combination therapy for pi3k-associated disease or disorder
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
WO2020223522A1 (en) 2019-04-30 2020-11-05 University Of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP2023529504A (ja) * 2020-06-14 2023-07-10 エル-ニュートラ・インコーポレイテッド ファスティング状態を維持及び延長する断続的なファスティングバー/ドリンク
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012009423A2 (pt) * 2009-10-22 2017-06-13 Univ Southern California método de alívio de crescimento de cãncer ou de um simtoma de cãncer, método de sensibilização de ccâncer a fármacos quimioterápicos, método de sensibilização de câncer à radioterapia e pacote de refeição terapêutica para fornecer refeições para um paciente com cãncer que retarda crescimento de cãncer e intensifica a eficácia de fármacos quimioterápicos
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
CN109187991B (zh) * 2013-02-12 2021-12-24 南加利福尼亚大学 为受试者提供合理蛋白质膳食的方法
WO2015002972A1 (en) * 2013-07-01 2015-01-08 University Of Southern California Fasting condition as dietary treatment of diabetes
JP6859567B2 (ja) * 2014-03-06 2021-04-14 ユニヴァーシティ オブ サザン カリフォルニアUniversity of Southern California 従来の化学療法剤の効力および実行可能性を増強し、かつ正常な細胞および組織におけるキナーゼの副作用を逆転させるための、キナーゼ阻害剤と併用した短期間絶食レジメンの使用

Similar Documents

Publication Publication Date Title
JP2018511625A5 (https=)
Chi et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer
Moorcraft et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience
RU2017136423A (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
Lewis et al. Feeding tube use in patients with head and neck cancer
KR102154458B1 (ko) 공복 조건들 하에서의 타시멜테온의 투여
JP2013508411A5 (https=)
JP2011144190A (ja) 抗癌剤の効果増強剤
Roy et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
JP2017503846A5 (https=)
Alberts et al. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial
JP2020523375A5 (https=)
Dubrey et al. Digital clubbing: forms, associations and pathophysiology
Jain et al. Radiation therapy as a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel
Sugimoto et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)
Hoang et al. Palliative treatment for advanced biliary adenocarcinomas with combination dimethyl sulfoxide–sodium bicarbonate infusion and S-adenosyl-l-methionine
Paz-Ares et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
Chalasani Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations
Kolb et al. Effective use of tocilizumab for the treatment of steroid‐refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin‐6
Chaudhary et al. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer
Crumbaker et al. Dose considerations for anti‐cancer drugs in metastatic prostate cancer
Melichar et al. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial
Sardi et al. Successful treatment with a low-dose cisplatin–etoposide regimen for patients with diencephalic syndrome
Assy et al. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study
Verslype et al. The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012